mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
The vaccine reportedly thwarted the cancer's return and spread.
Tech news from the best sources
The vaccine reportedly thwarted the cancer's return and spread.
Moderna's new flu vaccine, mFLUSIVA, is approved for all adults ages 50 and up.
The interim Phase I trial data was only from 35 people, but results look good so far.